drugset
drugset / Trial / NCT00386490

Safety of Larazotide Acetate in Healthy Volunteers

NCT00386490 ↗

Phase 1 Completed 24 enrolled 9 Meters Biopharma, Inc.
RandomizedSequentialDouble-blindBasic science

Summary

To demonstrate the safety, tolerance and pharmacokinetics of multiple, oral doses of larazotide acetate.

Timeline

Start
2006-01-10
Primary completion
2006-02-27
Completion
2006-02-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Larazotide Peptide 0.25 mg Oral
Subject Larazotide Peptide 1 mg Oral
Subject Larazotide Peptide 4 mg Oral

Indications

No indication recorded.